Optieum Biotechnologies
Optieum Biotechnologies is a preclinical-stage Japanese biotech that develops CAR-T cell therapies using its proprietary Eumbody System functional antibody screening platform, with a lead candidate targeting FAPα for glioblastoma and additional CD19 and undisclosed programs.
- Company typePrivate
- Founded2020
- HeadquartersMatsuyama-shi, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Optieum Biotechnologies does
Optieum Biotechnologies is a preclinical-stage biotechnology company founded in 2020 as a spin-off from Ehime University in Toon City, Ehime, Japan. It develops CAR-T cell therapies built on its proprietary Eumbody System, a functional antibody screening platform designed to identify disease-relevant binding constructs. The lead clinical candidate, OPTF01, is an autologous CAR-T directed against fibroblast activation protein alpha (FAPα) for glioblastoma; the broader pipeline extends to a CD19-directed program and an undisclosed additional target. The platform has been granted patents in the United States, Japan, and Australia, and the company has completed a pre-IND meeting with the US FDA for OPTF01.
The company's business model is currently research-driven rather than commercial: it is funded by a combination of equity capital (a ~$2.6M seed round and a ~$8.9M Series A) and non-dilutive grant support (up to ~$39M from AMED). Its commercial pathway is oriented toward out-licensing and collaborative development, evidenced by partnerships with Daiichi Sankyo, GI CELL, and Japan's National Cancer Center on the research side, and with US-based contract manufacturers Genezen and Cellipont for clinical-grade production. As a preclinical company, Optieum has no product revenue; future monetization is expected to come from milestone payments, royalties, and licensing arrangements tied to clinical advancement of its CAR-T assets.
Optieum Biotechnologies firmographics
Firmographics- Name
- Optieum Biotechnologies
- Legal name
- Optieum Biotechnologies Inc.
- Website
- https://optieumbio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Optieum Biotechnologies is a preclinical-stage Japanese biotech that develops CAR-T cell therapies using its proprietary Eumbody System functional antibody screening platform, with a lead candidate targeting FAPα for glioblastoma and additional CD19 and undisclosed programs.
- Ownership category
- akta.pro rank
Optieum Biotechnologies industry classification
Industry- Product category
- CAR-T Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Optieum Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Matsuyama-shi
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Optieum Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- CAR-T Therapy Development and Licensing: As a preclinical-stage biotechnology company, Optieum generates revenue through licensing its proprietary Eumbody System technology and CAR-T therapy candidates to pharmaceutical partners, including upfront payments, milestone payments upon achievement of development milestones, and royalties on future product sales.
- Research Collaborations: Optieum enters into research collaboration agreements with pharmaceutical companies such as Daiichi Sankyo, receiving undisclosed upfront payments and eligible for development milestone payments.
- CAR-NK Licensing (GI CELL Agreement): Under the Research License and Option Agreement with GI CELL, Optieum receives upfront option exercise fees, milestone payments upon successful achievement of development milestones, and royalties on future sales of products arising from the license.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Optieum Biotechnologies product offering
Product offeringCore offering
Optieum Biotechnologies develops next-generation CAR-T cell therapies for cancer treatment, anchored by its proprietary Eumbody System — a CAR discovery engine that uses empirical functional screening of scFv sequences to optimize CAR binding constructs. The company advances internal therapeutic candidates (lead program OPTF01 targeting FAPα for glioblastoma, plus CD19 and undisclosed programs) and licenses its platform and candidates to pharmaceutical partners for upfront payments, milestones, and royalties.
Product overview
Optieum Biotechnologies operates as a platform-and-product company in the CAR-T cell therapy space. The Eumbody System serves as the proprietary core discovery platform that enables identification and optimization of CAR binding constructs through empirical functional screening. OPTF01 is the company's lead clinical candidate derived from the Eumbody System, a FAPα-targeted CAR-T therapy targeting both tumor cells and the tumor microenvironment in glioblastoma.
Differentiator
Problem solved
Functional benefit
Products and services
- OPTF01 (FAPα-targeted CAR-T therapy)
- CD19 CAR-T Program
- Undisclosed CAR-T Program (PROGRAM-3)
- Daiichi Sankyo Research Collaboration (Eumbody System scFv discovery)
- GI CELL Research License and Option Agreement (CAR-NK)
Quantifiable outcome
- US Patent US 12,241,061 B granted for Eumbody System core platform technology
- +3 more outcomes
Companies that use Optieum Biotechnologies
Customer profileSegments4 records
Ideal customer profiles3 records
Optieum Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Optieum Biotechnologies partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Cellipont BioservicescoreCellipont Bioservices, a leading cell therapy CDMO, partnered with Optieum for cGMP manufacturing of OPTF01, Optieum's novel CAR-T therapy for glioblastoma. Cellipont provides technology transfer, process development, and cGMP manufacturing of the CAR-T product.
- GenezencoreGenezen, a leading viral vector CDMO, partnered with Optieum for cGMP manufacturing of the lentiviral vector (LVV) construct used in the production of OPTF01, Optieum's novel CAR-T therapy for glioblastoma treatment. Genezen provides technology transfer, process development, and cGMP manufacturing services.
- GI CELLcoreOptieum and GI CELL entered into a Research License and Option Agreement on CAR-NK Cell Therapy. GI CELL receives license to use Optieum's novel scFv antibodies with their NKPUREExpander® platform. Optieum receives upfront option exercise fee, milestone payments, and royalties on future product sales.
- National Cancer Center JapancoreOptieum and the National Cancer Center Japan (NCC-EPOC) entered into a joint research agreement to discover and develop innovative CAR-T cell therapy assets targeting solid tumors. The collaboration combines Optieum's scFv platform with NCC's clinical research expertise.
- Daiichi SankyocoreOptieum entered into a research collaboration with Daiichi Sankyo to use its Eumbody System technology to identify new functional scFvs for CAR-T cell therapy against a target of interest selected by Daiichi Sankyo. Optieum receives undisclosed upfront payment and is eligible for milestone payments.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Optieum Biotechnologies competitors and assessment
Company assessmentDirect peers
- Caribou Biosciences: Clinical-stage CAR-T cell therapy company developing allogeneic CAR-T candidates for hematological malignancies and solid tumors using genome-editing platforms. Directly comparable to Optieum as a CAR-T platform play with both platform technology and pipeline candidates advancing through IND and early clinical stages.
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T company with multiple candidates in clinical trials for hematological cancers and solid tumors. Comparable as a CAR-T-focused biotech whose business model centers on developing engineered T-cell therapies for oncology, though at a more advanced clinical stage.
- Fate Therapeutics: Clinical-stage cell therapy company developing iPSC-derived NK and T-cell cancer immunotherapies with multiple programs in solid tumor and hematological indications. Comparable to Optieum as a platform-based engineered cell therapy company targeting oncology with novel modality approaches.
- Precision BioSciences: Clinical-stage gene-editing company developing allogeneic CAR-T cell therapies (including for solid tumors) using its proprietary ARCUS genome editing platform. Directly comparable to Optieum's CAR-T platform approach; notably, Optieum CSO Dan MacLeod previously led CAR-T R&D at Precision.
- Cellectis: Clinical-stage gene-editing company developing allogeneic CAR-T cell therapies (UCART platform) for oncology. Comparable to Optieum as an engineered cell therapy platform company with candidates in both hematological and solid tumor indications, and with a similar gene-editing/scFv engineering discovery approach.
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies primarily for solid tumors, with one approved product (Tecelra). Comparable to Optieum in focusing on T-cell receptor-based therapies for solid tumor indications where conventional CAR-T has struggled.
- Adaptimmune (Tmunity equivalent): Note: Tmunity Therapeutics was acquired by Eli Lilly in 2023. As a historical comparable, Tmunity focused on engineered T-cell therapies for solid tumors using novel TCR and CAR constructs — directly parallel to Optieum's solid tumor CAR-T focus. Adaptimmune serves as the active, ongoing peer in this category.
Broad incumbents
- AbCellera Biologics: Clinical-stage biotechnology company with a proprietary antibody discovery platform generating therapeutic candidates for partners. Comparable to Optieum as a platform-based antibody discovery company, though AbCellera operates at much greater scale with an established partner business model spanning pharma and biotech.
- Bristol Myers Squibb: Global pharmaceutical company with two approved CAR-T products (Breyanzi for lymphoma, Abecma for multiple myeloma) acquired through the Celgene/Juno transactions. Comparable as a potential strategic acquirer/partner for Optieum given its established CAR-T commercial franchise and active interest in next-generation cell therapies.
- Daiichi Sankyo: Major Japanese pharmaceutical company and existing Optieum research collaborator (since 2021) using the Eumbody System to discover scFvs for CAR-T programs. Comparable as a relevant strategic partner and potential acquirer given its established CAR-T ambitions and existing commercial relationship with Optieum.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Optieum Biotechnologies social profiles
Digital presenceOptieum Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optieum Biotechnologies leadership team
Management profileNumber of profiles
Profiles10 records
Optieum Biotechnologies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optieum Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optieum Biotechnologies
What does Optieum Biotechnologies do?
Optieum Biotechnologies develops next-generation CAR-T cell therapies for cancer treatment, anchored by its proprietary Eumbody System — a CAR discovery engine that uses empirical functional screening of scFv sequences to optimize CAR binding constructs. The company advances internal therapeutic candidates (lead program OPTF01 targeting FAPα for glioblastoma, plus CD19 and undisclosed programs) and licenses its platform and candidates to pharmaceutical partners for upfront payments, milestones, and royalties.
Is Optieum Biotechnologies a public or private company?
Optieum Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Optieum Biotechnologies founded?
Optieum Biotechnologies was founded in 2020. It employs 11 to 50 people.
Where is Optieum Biotechnologies based?
Optieum Biotechnologies is headquartered in Matsuyama-shi, Japan, in the Asia region.
How does Optieum Biotechnologies make money?
Three revenue lines are on record. CAR-T Therapy Development and Licensing is the primary driver. The others are research Collaborations and CAR-NK Licensing (GI CELL Agreement).
Who are Optieum Biotechnologies's main competitors?
Direct peers on record are Caribou Biosciences, Allogene Therapeutics, Fate Therapeutics, Precision BioSciences, Cellectis, Adaptimmune Therapeutics and Adaptimmune (Tmunity equivalent). Broad incumbents are AbCellera Biologics, Bristol Myers Squibb and Daiichi Sankyo.
Does Optieum Biotechnologies have an API?
No public API is recorded for Optieum Biotechnologies.
What industry is Optieum Biotechnologies in?
Optieum Biotechnologies's product category is CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.